LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

STERIS PLC

Geschlossen

BrancheGesundheitswesen

252.04 2.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

243.99

Max

252.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

173M

Verkäufe

42M

1.4B

KGV

Branchendurchschnitt

37.416

56.602

EPS

2.32

Dividendenrendite

1.01

Gewinnspanne

12.643

Angestellte

18,000

EBITDA

44M

374M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+4.81% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.01%

2.45%

Nächstes Ergebnis

5. Aug. 2025

Nächste Dividendenausschüttung

26. Juni 2025

Nächstes Ex-Dividendendatum

10. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

23B

Vorheriger Eröffnungskurs

249.59

Vorheriger Schlusskurs

252.04

Nachrichtenstimmung

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

STERIS PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Mai 2025, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $9.90-Adj EPS $10.15 >STE

14. Mai 2025, 20:30 UTC

Ergebnisse

Steris 4Q Rev $1.5B >STE

14. Mai 2025, 20:30 UTC

Ergebnisse

Steris 4Q Adj EPS $2.74 >STE

5. Feb. 2025, 21:35 UTC

Ergebnisse

Steris: Outlook Does Not Reflect Any Potential Impact From New Tariffs >STE

5. Feb. 2025, 21:34 UTC

Ergebnisse

Steris: FY25 Guidance Change Is Primarily Due to Currency >STE

5. Feb. 2025, 21:34 UTC

Ergebnisse

Steris Cuts FY25 Revenue View to Increase of About 6% From Prior View for 6.5%-7%>STE

5. Feb. 2025, 21:33 UTC

Ergebnisse

Steris 3Q EPS $1.75 >STE

5. Feb. 2025, 21:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $9.05-Adj EPS $9.15 >STE

5. Feb. 2025, 21:30 UTC

Ergebnisse

Steris 3Q Rev $1.4B >STE

5. Feb. 2025, 21:30 UTC

Ergebnisse

Steris 3Q Adj EPS $2.32 >STE

6. Nov. 2024, 21:41 UTC

Ergebnisse

Steris Backs FY25 Revenue Up 6.5%-7.5% >STE

6. Nov. 2024, 21:40 UTC

Ergebnisse

Steris 2Q EPS $1.51 >STE

6. Nov. 2024, 21:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

6. Nov. 2024, 21:30 UTC

Ergebnisse

Steris 2Q Adj EPS $2.14 >STE

6. Nov. 2024, 21:30 UTC

Ergebnisse

Steris 2Q Rev $1.3B >STE

6. Aug. 2024, 20:36 UTC

Ergebnisse

Steris 1Q Adj EPS $2.03 >STE

6. Aug. 2024, 20:30 UTC

Ergebnisse

Steris 1Q Net $139.9M >STE

6. Aug. 2024, 20:30 UTC

Ergebnisse

Steris 1Q EPS $1.41 >STE

6. Aug. 2024, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

3. Juni 2024, 11:03 UTC

Akquisitionen, Fusionen, Übernahmen

PEAK ROCK Cap Affil COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION of HUFRIEDYGROUP

31. Mai 2024, 20:47 UTC

Akquisitionen, Fusionen, Übernahmen

Steris Completes $787.5M Sale of Dental Segment to Peak Rock Capital

Peer-Vergleich

Kursveränderung

STERIS PLC Prognose

Kursziel

By TipRanks

4.81% Vorteil

12-Monats-Prognose

Durchschnitt 258.75 USD  4.81%

Hoch 280 USD

Tief 240 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für STERIS PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

225 / 226.35Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

173 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über STERIS PLC

STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.